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Abstract
Glycine transporter-1 (GlyT-1) in glial cells regulates extracellular levels of glycine, which acts as an obligatory co-agonist at
the N-methyl-D-aspartate (NMDA) receptors in the brain. In the present study, we developed a novel radioligand, [
3H]3-
chloro-N-((S)-((R)-1-methylpiperidin-2-yl)(thiophen- 3-yl)methyl)-4- (trifluoromethyl)picolinamide ([
3H]CHIBA-3007), for
studying GlyT-1 in the brain. The presence of a single saturable high-affinity binding component for [
3H]CHIBA-3007
binding to the rat brain membranes was detected. Scatchard analysis revealed an apparent equilibrium dissociation
constant (Kd) of 1.6160.16 nM and a maximal number of binding sites (Bmax) of 692.8622.8 fmol/mg protein (mean 6 SEM,
n=3). The specific binding of [
3H]CHIBA-3007 was inhibited by a number of GlyT-1 inhibitors, such as CHIBA-3007,
desmethyl-CHIBA-3007, CHIBA-3008, SSR504734, NFPS/ALX5407, LY2365109 and Org24598, consistent with the
pharmacological profiles of GlyT-1 inhibitors. Interestingly, the potency of eight GlyT-1 inhibitors (CHIBA-3007,
desmethyl-CHIBA-3007, NFPS/ALX5407, LY2365109, Org24598, SSR504734, sarcosine, and glycine) for blocking in vitro
specific binding of [
3H]CHIBA-3007 was significantly correlated with the potency of these inhibitors for inhibiting
[
14C]glycine uptake in the rat brain membranes. In contrast, the GlyT-2 inhibitor ALX1393 exhibited very weak for [
3H]CHIBA-
3007 binding. Furthermore, the regional distribution of [
3H]CHIBA-3007 binding in the rat brain was similar to the previously
reported distribution of GlyT-1. The present findings suggest that [
3H]CHIBA-3007 would be a useful new radioligand for
studying GlyT-1 in the brain.
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Introduction
Glycine plays an important role in excitatory neurotransmis-
sion via strychnine-insensitive glycine sites located on the N-
methyl-D-aspartate (NMDA) receptor [1–4]. In the central
nervous system (CNS), synaptic levels of glycine are regulated
by specific sodium/chloride-dependent transporters. The actions
of glycine are terminated by reuptake via two high-affinity glycine
transporters referred to as glycine transporter 1 (GlyT-1) and
glycine transporter 2 (GlyT-2). GlyT-1 and GlyT-2 possess 12
putative transmembrane spanning domains, and share approxi-
mately 50% amino acid sequence identity [1–4]. GlyT-1 is widely
expressed in the CNS, where it is present predominantly on glial
cells. It is likely that GlyT-1 is responsible for glycine reuptake in
forebrain areas, and in some regions it may be co-localized with
strychnine-insensitive glycine sites on the NMDA receptor [5–
11]. In contrast to GlyT-1, the distribution of GlyT-2 is
predominantly neuronal and much more limited, being mainly
restricted to the spinal cord, brainstem and cerebellum [9,12].
Indeed, GlyT-2 is co-localized with strychnine-sensitive glycine
receptors, suggesting that GlyT-2 may be a reliable marker for
glycinergic neurons [1–4,12,13].
Accumulating evidence suggests that a dysfunction in glutama-
tergic neurotransmission via the NMDA receptors plays a role in
the pathophysiology of schizophrenia [14–19]. Therefore, the
potentiation of NMDA receptor function could provide a new
approach for the treatment of neuropsychiatric diseases associated
with NMDA receptor hypofunction. The effective therapeutic
strategy is to increase synaptic levels of glycine by blocking the
GlyT-1 in glial cells, because glycine is a co-agonist on the NMDA
receptor [20–28].
Considering these results together, it would be of great interest
to develop radioligands for studying GlyT-1 in the brain.
Previously, two sarcosine-based GlyT-1 inhibitors, including
[
3H]NFPS [29], [
3H](R)-NPTS [30,31], have been reported.
However, these two radioligands may be less suitable radioligands
for studying GlyT-1 since these radioligands are non-competitive
with respect to glycine [32,33]. Recently, some non-sarcosine-
based radioligands such as [
3H]N-methyl-SSR504734 [31],
[
3H]SB-733993 and [
3H]GSK931145 [33] have been developed.
3-Chloro-N-((S)-((R)-1-methylpiperidin-2-yl)(thiophen-3-yl)methyl)
-4-(trifluoromethyl)picolinamide (CHIBA-3007)(Figure 1), is a novel
non-sarcosine-based GlyT-1 inhibitor. We found that CHIBA-3007
was a more potent GlyT-1 inhibitor than SSR504734 (this
study). In the present study, we report the characterization of a
new radioligand [
3H]CHIBA-3007 binding to GlyT-1 in the rat
brain.
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Affinity and specificity of CHIBA-3007 for GlyT-1
The IC50 values of CHIBA-3007 and SSR504734 for [
14C]gly-
cine (10 mM) uptake in the rat brain membrane were 21.468.4 nM
(n=3, mean 6 S.E.M.) and 84.5629.8 nM (n=3, mean 6
S.E.M.), respectively. Thus, CHIBA-3007 was more potent than
SSR504734 for glycine uptake inhibition. Furthermore, CHIBA-
3007 (1 mM) was found to be devoid of activity (inhibition lower
than 50%) for a 28 standard target binding profile (Table S1).
Synthesis of [
3H]CHIBA-3007
[
3H]CHIBA-3007 was synthesized by methylation of the
precursor (Figure S1). The radiochemical purity and specific
activity of [
3H]CHIBA-3007 were 98.9% and 2960 GBq/mmol
(based on the specific activity of [
3H]methyl iodide), respectively.
The radiochemical yield of [
3H]CHIBA-3007 was 13%.
Equilibrium saturation binding of [
3H]CHIBA-3007 to rat
brain membranes
For saturation-binding isotherms, 6 grade-diluted concentrations
of [
3H]CHIBA-3007 (0.3125–10 nM) were used. Specific binding
of [
3H]CHIBA-3007 to rat brain membranes was saturable and
rapid, and represented .90% of total binding over the concentra-
tion range of [
3H]CHIBA-3007 (Figure 2). In saturation-binding
isotherms, nonlinear regression analysis of specific binding revealed
an apparent Kd of 1.6160.16 nM (95% confidence interval: 1.267
to 1.945 nM) and a Bmax of 692.8622.8 fmol/mg protein (95%
confidence interval: 644.5 to 741.1 fmol/mg protein) (n=3, mean
6 S.E.M.) at room temperature (Figure 2).
Pharmacological profiles of [
3H]CHIBA-3007 binding to
rat brain membranes
The pharmacological inhibition of specific [
3H]CHIBA-3007
(1 nM) binding to rat brain membranes was examined. Ten
compounds, i.e., desmethyl-CHIBA-3007, CHIBA-3007, CHIBA-
3008, SSR504734, NFPS/ALX5407, LY2365109, Org24598,
glycine, sarcosine and ALX1393, were found to displace
[
3H]CHIBA-3007 binding to rat brain membranes (Figure 3).
The Ki values of CHIBA-3008, CHIBA-3007, NFPS/ALX5407,
LY2365109, Org24598, SSR504734 and desmethyl-CHIBA-3007
were 2.2, 2.8, 4.1, 16.2, 16.9, 24.6 and 35.9 nM, respectively
(Table 1). The Ki values of the endogenous substances sarcosine
and glycine for [
3H]CHIBA-3007 binding were 103.5 mM and
287.9 mM, respectively. In contrast, the GlyT-2 inhibitor
ALX1393 had very low affinity at [
3H]CHIBA-3007 binding
(851.7 nM)(Table 1).
The potency of eight GlyT-1 inhibitors (CHIBA-3007, des-
methyl-CHIBA-3007, NFPS/ALX5407, LY2365109, Org24598,
SSR504734, sarcosine, and glycine) for blocking specific binding of
[
3H]CHIBA-3007 was significantly (r=0.943, p,0.0001) correlat-
ed with that of these inhibitors for inhibiting [
14C]glycine uptake in
the same samples (Figure 4). Furthermore, there was also a
significant (r=0.981,p=0.003) correlation between the potency for
inhibition of [3H]CHIBA-3007 binding and the potency of drug
inhibition for [3H]N-methyl-SSR504734 binding (data from [31])
(Figure 5).
Regional distribution of [
3H]CHIBA-3007 binding in the
rat brain
The regional distribution of [
3H]CHIBA-3007 binding in the rat
brain is shown in Figure 6. Specific [
3H]CHIBA-3007 binding was
higher in the midbrain and lower in the cerebral cortex. The order of
specific binding of [
3H]CHIBA-3007 in the rat brain was as follows:
midbrain . pons . thalamus . cerebellum . striatum .
hippocampus . cerebral cortex. The regional distribution of
[
3H]CHIBA-3007 binding in the rat brain was similar to the
distribution of GlyT-1 in the rat brain reported previously [6,9,10,32].
Discussion
The present study shows that [
3H]CHIBA-3007, a non-
sarcosine-based GlyT-1 inhibitor, is a novel and excellent
Figure 1. Chemical structure of GlyT-1 inhibitors used in this study.
doi:10.1371/journal.pone.0021322.g001
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GlyT-1 in the rat brain in vitro. The major findings of the present
study are summarized as follows. First, the potency (IC50=
21.4 nM) of CHIBA-3007 for inhibiting [
14C]glycine uptake in the
rat brain was higher than that (IC50=84.5 nM) of SSR504734, a
potent, selective, and orally active GlyT-1 inhibitor [34].
Furthermore, CHIBA-3007 did not show any affinity (less than
50% at 1 mM) for a 28 standard target binding profile (Table S1),
suggesting the high selectivity of CHIBA-3007 for GlyT-1.
Second, the kinetic study showed that the specific binding of
[
3H]CHIBA-3007 to rat brain membranes reached equilibrium
rapidly (less than 5 min, data not shown). Furthermore, Scatchard
analysis showed that [
3H]CHIBA-3007 selectively binds to rat
brain with a high affinity (Kd=1.61 nM). Nonspecific binding of
[
3H]CHIBA-3007 to rat brain membranes was very low (,10%).
Third, specific binding of [3H]CHIBA-3007 was inhibited by
several compounds, including CHIBA-3008, CHIBA-3007,
NFPS/ALX5407, LY2365109, Org24598, SSR504734, des-
methyl-CHIBA-3007, sarcosine and glycine. Interestingly, there
was a significant positive correlation between the Ki values
obtained from the drug inhibition of [
3H]CHIBA-3007 binding
Figure 2. Specific binding of [
3H]CHIBA-3007 to rat brain membranes. Rat brain membranes were incubated with various concentrations of
[
3H]CHIBA-3007 (0.3125–10 nM) for 120 min at room temperature. Nonspecific binding was estimated in the presence of 10 mM SSR504734. The
results are from a typical experiment and values are the average of duplicate determinations. (A): The saturation binding isotherm shows specific
binding of [
3H]CHIBA-3007. TB: total binding, NSB: nonspecific binding, SB: specific binding. The results are means 6 S.E.M. of three independent
experiments performed in duplicate. (B): Scatchard plot analysis of [
3H]CHIBA-3007 binding gave a Kd of 1.61 nM (95% confidence interval: 1.27 to
1.95 nM) and a Bmax of 692.8 fmol/mg protein (95% confidence interval: 644.5 to 741.1 fmol/mg protein). The data are the mean of three
independent experiments performed in duplicate.
doi:10.1371/journal.pone.0021322.g002
Figure 3. Competition curves of [
3H]CHIBA-3007 binding by
drugs. Inhibition curves for the displacement of [
3H]CHIBA-3007 (1 nM)
binding to rat brain membranes were obtained by 10 compounds such
as CHIBA-3007, desmethyl-CHIBA-3007, CHIBA-3008, SSR504734, NFPS/
ALX-5407, LY2365109, Org24598, glycine, sarcosine and ALX1393. The Ki
denotes the affinity constant for binding to a single state of binding
sites. The results are means 6 S.E.M. of three independent experiments
performed in duplicate.
doi:10.1371/journal.pone.0021322.g003
Table 1. Drug inhibition of [3H]CHIBA-3007 binding to rat
brain membranes.
Compounds Ki (nM)
CHIBA-3008 2.260.6
CHIBA-3007 2.860.17
NFPS/ALX5407 4.160.9
LY2365109 16.264.9
Org24598 16.963.1
SSR504734 24.660.8
Desmethyl-CHIBA-3007 35.961.3
ALX1393 851.7656.4
Sarcosine 103,492610,572
Glycine 287,921626,807
The inhibition of [
3H]CHIBA-3007 binding by various drugs was determined
with [
3H]CHIBA-3007 (1 nM). Nine concentrations of the drugs were used for
each determination. Ki values for the various drugs were determined as
described in experimental procedures. The values represent the mean 6 S.E.M
of three independent experiments performed in duplicate.
doi:10.1371/journal.pone.0021322.t001
[
3H]CHIBA-3007 Binding to Glycine Transporter 1
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e21322and the IC50 values obtained from drug inhibition of [
14C]glycine
uptake in the rat brain. Furthermore, we found a significant
correlation between the potency of five compounds (NFPS/
ALX5407, SSR504734, Org24598, sarcosine and glycine) for
[
3H]CHIBA-3007 binding and [
3H]N-methyl-SSR504734 binding
[31]. Finally, the regional distribution of [
3H]CHIBA-3007 binding
in the rat brain was consistent with previous reports on the
localization of GlyT-1 mRNA and GlyT-1 protein using in situ
hybridization, immunohistochemistry [6,9,10], and [35S](S)-2-
amino-4-chloro-N-(1-(4-phenyl- 1-(propylsulfonyl)piperidin-4-yl)ethyl)
benzamide: ACPPB) binding [32]. Taken all together, the present
findings suggest that [
3H]CHIBA-3007 binding sites could be
associated with GlyT-1 in the rat brain.
Very recently, two non-sarcosine-based radioligands, [
3H]SB-
733993 and [
3H]GSK931145, have been developed [33]. The
potencies of SB-733993 (pIC50=7.20) and GSK931145 (pIC50=
7.58) for inhibiting [
3H]glycine uptake were more potent than
that of SSR504734 (pIC50=6.52) [33]. [
3H]SB-733993 and
[
3H]GSK931145 showed similar binding affinities for GlyT-1 and
similar levels of specific binding. For both radioligands, the specific
binding at concentrations around Kd values (1–2 nM) represented
.90% of total binding [33], indicating low non-specific binding.
However, the Bmax values of both radioliagnds in the rat brain were
higher (around 3000 fmol/mg protein) than the Bmax values
(692.8 fmol/mg protein) using [
3H]CHIBA-3007. The reasons
underlying this discrepancy are currently unclear. One possibility
may be due to the differences in the methodology of sample
preparation, and binding assay. Furthermore, non-sarcosine-based
GlyT-1 inhibitors as well as glycine itself all showed competitive
interactions with the binding of [
3H]SB-733993 and [
3H]GS-
K931145, whereas the sarcosine-based GlyT-1 inhibitors (NFPS/
ALX5407 and Org25935) showed uncompetitive interactions with
the bindings of both radioligands [33]. It is, therefore, likely that,
similar to other non-sarcosine radioliagnds (e.g., [
3H]SB-733993,
[
3H]GSK931145), [
3H]CHIBA-3007 might bind to sites on the
GlyT-1 that are orthosteric to the site at which glycine itself binds.
Previously, we reported that repeated administration of the
NMDA receptor antagonist phencyclidine caused an increase of
GlyT-1 protein as well as a reduction of extracellular glycine levels
in the hippocampus, but not the frontal cortex [35]. The study
suggests that increased GlyT-1 protein may play a role in
removing the extracellular glycine in the synaptic cleft via GlyT-
1, resulting in lower extracellular levels of glycine in the
hippocampus [35]. To date, there has been no report about
GlyT-1 density in the hippocampus of patients with schizophrenia,
although it has been reported that GlyT-1 mRNA and protein
levels were not altered in the prefrontal cortex and cerebellum of
postmortem brain samples from patients with schizophrenia [36].
Therefore, it would be of interest to study whether levels of GlyT-1
Figure 4. Comparison between the potency of various drugs
for inhibiting [
3H]CHIBA-3007 binding and [
14C]glycine uptake
into the rat brain membranes. Data are from Table 1 and Table 2.
There was a significant (r=0.943, p,0.0001) correlation between the
potency for inhibiting of 8 compounds (desmethyl-CHIBA-3007, CHIBA-
3007, NFPS/ALX5407, SSR504734, Org24598, LY2365109, sarcosine and
glycine) for [
3H]CHIBA-3007 binding and [
14C]glycine uptake.
doi:10.1371/journal.pone.0021322.g004
Figure 5. Comparison between Ki values of various drugs for
inhibiting [
3H]CHIBA-3007 binding and [
3H]N-methyl-
SSR504734 binding. Data of [
3H]CHIBA-3007 are from Table 1. There
was a significant (r=0.981, p=0.003) correlation between the potency
for inhibiting of 5 compounds (NFPS/ALX5407, SSR504734, Org24598,
sarcosine and glycine) for [
3H]CHIBA-3007 binding and [
3H]N-methyl-
SSR504734 binding [31].
doi:10.1371/journal.pone.0021322.g005
Table 2. Drug inhibition of [
14C]glycine uptake to rat brain
membranes.
Compounds IC50 (nM)
[
14C]Glycine uptake
CHIBA-3007 21.468.4
NFPS/ALX5407 83.7630.3
SSR504734 84.5629.8
Desmethyl-CHIBA-3007 187.2640.0
Org24598 653.36154.1
LY2365109 1,350689.2
Glycine 338,766618,285
Sarcosine 414,376627,250
The inhibition of [
14C]glycine uptake by various drugs was determined as
described in the method. Nine concentrations of the drugs were used for each
determination. The values represent the mean 6 S.E.M of three independent
experiments performed in duplicate.
doi:10.1371/journal.pone.0021322.t002
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schizophrenia using a [
3H]CHIBA-3007-binding assay. Nonethe-
less, a further characterization of [
3H]CHIBA-3007 binding in the
postmortem brain sample from human is needed.
In conclusion, the present study shows that [
3H]CHIBA-3007
binding sites are associated with GlyT-1 in the rat brain and that
[
3H]CHIBA-3007 could be a highly and specific and selective
radioligand for studying GlyT-1 function in the brain in vitro.
Materials and Methods
Materials
CHIBA-3007, 3-chloro-N-((S)-((R)-piperidin-2-yl)(thiophen-3-yl)me-
thyl)-4- (trifluoromethyl)picolinamide (desmethyl-CHIBA-3007),
N-((S)-(3-(1H-pyrazol-4-yl)phenyl)((R)-piperidin-2-yl)methyl)-3-chloro-
4-(trifluoromethyl)pyridine-2-carboxamide (CHIBA-3008: Taisho
Pharmaceutical Ltd., Compound 86 [37], and SSR504734
(Figure 1) were synthesized by the previously reported methods
[37,38] with slight modification. CHIBA-3008 is a very potent
inhibitor of GlyT-1 (IC50=0.2nMfor[
3H]glycine uptake) [37].
The following drugs were obtained from the following sources:
NFPS/ALX5407 (N- [3-(4-fluorophenyl)-3-(4-phenyl-phenoxy)-
propyl]-sarcosine) and LY2365109 ({[2-(4-benzo[1,3]dioxol-5-yl-
2- tert-butylphenoxy)ethyl]-methylamino}) sarcosine (Figure 1)
were purchased from Tocris Bioscience (Bristol, UK); Org24598
((R,S)-(6)N-methyl-N-[(4-trifluoromethyl)phenoxy]-3-phenylpropy-
lglycine) (Figure 1), glycine, and O-[(2-benzyloxyphenyl-3-flurophe-
nyl)methyl]-L-serine (ALX1393) were purchased from Sigma-
Aldrich (St. Louis, MO). [
3H]Methyl iodide (2.96 TBq/mmol)
and [
14C]glycine (3.96 GBq/mmol) were purchased from Ameri-
can Radiolabeled Chemicals Inc. (St. Louis, MO) and PerkinElmer
Life & Analytical Sciences (Boston, MA), respectively.
Synthesis of [
3H]CHIBA-3007
[
3H]CHIBA-3007 was synthesized by N-methylation of the
desmethyl-CHIBA-3007 with [
3H]methyl iodide (Figure S1). The
0.1 mL of [
3H]methyl iodide toluene solution (370 MBq) was
added to an ice-cold reaction vessel containing desmethyl-CHIBA-
3007 (4 mg) and potassium carbonate (1.5 mg) in N,N-dimethyl-
formamide (DMF, 0.3 mL). The reaction vessel was stirred at 0uC
for 30 min. The reaction mixture was applied to a high
performance liquid chromatography (HPLC) using an YMC Pack
ODS-A column (10 mm in inner diameter 6250 mm in length;
YMC Co., Ltd., Kyoto, Japan), comprised of UV absorbance
(270 nm). A mixture of CH3CN/50 mM CH3COONH4/
CH3COOH (350/650/3) was used as the mobile phase at a flow
rate of 4 mL/min. The column eluent was collected automatically
by using a fraction collector (Model 2110; Bio-Rad Laboratories,
K.K., Tokyo, Japan) directly into polypropylene tubes. The 10-mL
of each collected fractions were sampled into glass vials with 4 ml
of scintillation cocktail (ACS-II; GE Healthcare Japan K.K.,
Tokyo, Japan). The radioactivity was determined using a liquid
scintillation counter (LS-6500; Beckman Coulter, Tokyo, Japan).
The radioactive fraction, eluted with a retention time correspond-
ing to that of the authentic standard by was collected into an
evaporation flask and evaporated to dryness. The residue was re-
dissolved with 2 ml of ethanol. Chemical and radiochemical purity
of [
3H]CHIBA-3007 was analyzed by HPLC in a system
consisting of a column (YMC-Pack Pro C18, 4.6 mm in inner
diameter 6250 mm in length, YMC Co., Ltd., Kyoto, Japan),
using CH3CN/50 mM CH3COONH4/CH3COOH (350/650/3)
as a mobile phase at a flow rate of 1.0 ml/min.
Preparation of Rat Brain Membrane
Male Crl: CD (SD) SPF/VF rats (8–10 week olds, 180–
200 g)(Japan Charles River Inc., Tokyo, Japan) were used for the
experiments. All animal studies were approved by the Animal
Care and Use Committee of Chiba University (Permit Number:
22–122). All experiments were performed according to the
Guidelines for Animal Experimentation and also conformed to
the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health. All efforts were made to
minimize suffering.
After sacrificing the rats by decapitation, the brains were rapidly
removed from the skulls. Whole brains or seven specific cerebral
regions - the cerebral cortex, striatum, hippocampus, thalamus,
midbrain, cerebellum and pons - dissected on ice by the method of
Glowinski and Iversen [39] were stored at 280uC until use for the
assay.
For the [
3H]CHIBA-3007-binding assay, the tissues of whole
brains or each specific brain region were homogenized in 15
volumes (w/v) of 10 mM 4-(2-hydroxyethyl)-1- piperazineethane-
sulfonic acid (HEPES) at pH 7.4 for 30 s on ice. The homogenate
was centrifuged at 40,000 g for 15 min at 4uC. The supernatant
was discarded and the pellet was re-suspended, homogenized and
centrifuged as above. The membrane pellet was washed and re-
suspended in ice-cold HEPES buffer and was then centrifuged
three times. The final pellet was re-suspended in 15 volumes of the
buffer (120 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2
10 mM HEPES, pH 7.5 at room temperature).
For [
14C]glycine uptake, whole brains were homogenized in 10
volumes (w/v) of 0.32 M sucrose, buffered with 10 mM HEPES
(pH 7.4). The homogenate was centrifuged at 1,000 g for 10 min
to remove nuclei and debris, and then the supernatant was
centrifuged again at 20,000 g for 20 min (synaptosomal P2
fraction). The pellet was washed and re-suspended in ice-cold
0.32 M sucrose, buffered with 10 mM HEPES (pH 7.4) and
centrifuged again at 20,000 g for 20 min (washed P2 fraction). The
pellet was re-suspended in 10 volumes of assay buffer with the
following composition: 10 mM HEPES buffer (pH 7.4) containing
140 mM NaCl, 5.5 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4,
5 mM glucose and 5 mM L-alanine (HB). The protein concen-
Figure 6. Regional distribution of [
3H]CHIBA-3007 binding in
rat brain. The regional distribution of [
3H]CHIBA-3007 (1 nM) in the rat
brain was determined. The radioactivity of the regions was in the order
midbrain . pons . thalamus . cerebellum . striatum . hippocam-
pus . cerebral cortex. The results are means 6 S.E.M. of four
independent experiments performed in duplicate.
doi:10.1371/journal.pone.0021322.g006
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Laboratories Inc., Tokyo, Japan).
[
3H]CHIBA-3007 Binding Assay
Assays of the binding of [
3H]CHIBA-3007 to rat brain
membranes were performed. Aliquots of the rat brain membrane
suspension (200 mL) were added in duplicate to a reaction mixture
containing [
3H]CHIBA-3007 and the indicated concentrations of
test drug in a final volume of 0.5 mL. Non-specific binding was
estimated in the presence of 10 mM SSR504734, a potent and
selective GlyT-1 inhibitor [34]. [3H]CHIBA-3007 binding was
allowed to occur for 120 min at room temperature for the
equilibrium saturation and inhibition studies. The binding
reaction was terminated by rapid vacuum filtration onto Whatman
GF/B glass filters pretreated with 0.5% polyethyleneimine (Sigma-
Aldrich Co.) using a 24-channel cell harvester (Brandell,
Gaithersburg, MD). The filters were washed with 5 mL of ice-
cold assay buffer 3 times, and placed in vials with 4 mL
scintillation cocktail. The radioactivity trapped by the filters was
determined using a liquid scintillation counter (Beckman LS-6500;
Beckman Coulter K.K., Tokyo, Japan).
To examine the pharmacological profiles of [
3H]CHIBA-3007
binding, ten compounds were used: desmethyl-CHIBA-3007,
CHIBA-3007, CHIBA-3008, SSR504734, NFPS/ALX5407,
LY2365109, Org24598, glycine, sarcosine and ALX1393.
Inhibition of [
14C]glycine Uptake
The assay of [
14C]glycine uptake was started by adding 10 mM
[
14C]glycine to 200 mL of rat brain membrane in HB. The
inhibition of [
14C]glycine uptake by eight compounds—
desmethyl-CHIBA-3007, CHIBA-3007, SSR504734, NFPS/
ALX5407, LY2365109, Org24598, sarcosine and glycine—was
performed for 15 min at 37uC as reported previously [34]. Non-
specific uptake was estimated in the presence of 30 mM
SSR504734. The uptake of [
14C]glycine was terminated by rapid
vacuum filtration onto Whatman GF/B glass filters pretreated
with 0.5% polyethyleneimine. The filters were washed by buffer,
and the radioactivity trapped by the filters was determined using a
liquid scintillation counter as described above.
Statistical Analysis
The data are shown as the mean 6 standard error of the mean
(S.E.M.). The dissociation constant (Kd) and maximal binding
(Bmax) values from saturation binding and the IC50 values from
binding displacement by each drug were determined using the
program GraphPad Prism (GraphPad Software, San Diego, CA).
The Ki values were calculated from the IC50 values using the
formula of Chung and Prusoff, Ki=IC 50/(1+[L]/Kd) [40], where
the IC50 was the concentration that resulted in 50% inhibition of
specific binding, [L] was the concentration of radioligand used and
Kd was the dissociation constant. Correlation was analyzed by
Pearson’s Correlation Coefficient (PASW Statistics 19, Tokyo,
Japan). Significance was set at p,0.05.
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